Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Palvella's Phase III Success And Fast Track Status Test Current Valuation [Yahoo! Finance]
Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $210.00 to $240.00. They now have a "buy" rating on the stock.
Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]